Holen Sie sich die Stockscreener-App
1.89
13.17%
0.22
Schlusskurs vom Vortag:
$1.67
Offen:
$1.67
24-Stunden-Volumen:
1.10M
Relative Volume:
1.76
Marktkapitalisierung:
$199.14M
Einnahmen:
$15.53M
Nettoeinkommen (Verlust:
$-52.71M
KGV:
-3.7612
EPS:
-0.5025
Netto-Cashflow:
$-59.00M
1W Leistung:
+31.25%
1M Leistung:
+25.17%
6M Leistung:
-10.00%
1J Leistung:
-2.58%
1-Tages-Spanne:
$1.67
$1.97
1-Wochen-Bereich:
$1.43
$1.97
52-Wochen-Spanne:
$1.33
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Firmenname
Proqr Therapeutics N V
Sektor
Branche
Telefon
-
Adresse
-
Compare PRQR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.89 | 199.14M | 15.53M | -52.71M | -59.00M | -0.5025 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-29 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Herabstufung | Stifel | Buy → Hold |
| 2022-02-01 | Eingeleitet | Raymond James | Strong Buy |
| 2021-05-03 | Eingeleitet | Stifel | Buy |
| 2021-03-25 | Bestätigt | Citigroup | Buy |
| 2020-11-03 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-12-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-15 | Eingeleitet | Citigroup | Buy |
| 2018-09-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-09-26 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-06-20 | Eingeleitet | Chardan Capital Markets | Neutral |
| 2014-10-15 | Eingeleitet | Deutsche Bank | Buy |
| 2014-10-13 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
ProQR Therapeutics NV (PRQR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProQR Therapeutics NV (PRQR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProQR Therapeutics NV (PRQR) Institutional Confidence - TradingKey
ProQR Therapeutics NV (PRQR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProQR Therapeutics NV (PRQR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProQR Therapeutics NV (PRQR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ProQR Therapeutics NV (PRQR) Valuation: PE, PB & Fair Value Analysis - TradingKey
ProQR Therapeutics NV (PRQR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ProQR Therapeutics NV (PRQR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline - Eastern Progress
ETFs Investing in ProQR Therapeutics N.V. Stocks - TradingView
ProQR Therapeutics (PRQR) Advances 3% as Biotech Sector Sentiment ImprovesPCR Extreme - newsline.com
Undervalued Penny Stocks To Consider In June 2026 - simplywall.st
Van Herk group (NASDAQ: PRQR) challenges ProQR 2026 AGM share capital proposals - Stock Titan
ProQR Therapeutics N.V. (PRQR) director awarded 14,495 stock options as compensation - Stock Titan
ProQR Shareholders Approve Capital Increase, Board Changes at 2026 AGM - TipRanks
ProQR (PRQR) director Hinsch Gylvin Lykke files Form 3 with no share activity - Stock Titan
ProQR Therapeutics N.V. Appoints Lykke Hinsch Gylvin as Non-Executive Member of the Board, Effective June 2, 2026 - marketscreener.com
PRQR News | PROQR THERAPEUTICS NV (NASDAQ:PRQR) - ChartMill
PRQR Stock Price, Quote & Chart | PROQR THERAPEUTICS NV (NASDAQ:PRQR) - ChartMill
ProQR Therapeutics Holds Steady Above Support; Small Uptick Signals StabilityBullish Pattern Stocks - The Legal Advocate
Citizens reiterates ProQR stock rating on biliary atresia potential By Investing.com - Investing.com Australia
Citizens reiterates ProQR stock rating on biliary atresia potential - Investing.com
ProQR Therapeutics (PRQR) Holds Steady Near $1.57 as Uplift Potential RemainsDaily Profile - The Legal Advocate
ProQR (PRQR) Eyes Next Move After Holiday Ahead of AX-0810 Data - Bez Kabli
ProQR Therapeutics Q1 2026 Earnings: Narrower Net Loss, No Revenue as Pipeline Progress Drives Stock GainsWall Street Picks - Newser
Cash per share of ProQR Therapeutics N.V. – LS:A12B97 - TradingView
ProQR Therapeutics Q1 2026 Earnings: Narrower Loss on Continued Pipeline ProgressEarnings Quality Score - newsline.com
ProQR Therapeutics N.V. (PRQR) Presents at 29th ASGCT Annual Meeting 2026Slideshow - Seeking Alpha
ProQR Therapeutics N.V. (PRQR) Presents at TIDES USA 2026Slideshow (NASDAQ:PRQR) 2026-05-15 - Seeking Alpha
ProQR Therapeutics N.V.Ordinary Shares (NQ: PRQR - The Chronicle-Journal
ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22% - Yahoo Finance
ProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash Position - The Globe and Mail
ProQR Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
ProQR Posts Q1 2026 Results as Axiomer RNA Editing Pipeline Advances - TipRanks
ProQR Announces First Quarter 2026 Operating and Financial Results - The Manila Times
ProQR (Nasdaq: PRQR) Q1 2026 results, Axiomer pipeline and cash runway - Stock Titan
ProQR (Nasdaq: PRQR) updates AX-0810 strategy and Q1 2026 results - Stock Titan
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform - The Manila Times
ProQR Announces Multiple Upcoming Scientific Conference - GlobeNewswire
MSN Money - MSN
Number of shareholders of ProQR Therapeutics N.V. – LS:A12B97 - TradingView
ProQR Therapeutics (PRQR) to Release Quarterly Earnings on Thursday - MarketBeat
ProQR Sets June 2, 2026 Date for Annual General Meeting of Shareholders - The Globe and Mail
ProQR forms advisory board, partnership with Ginkgo as part of AI strategy - MSN
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 - markets.businessinsider.com
Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):